ABSTRACT
Toxic shock syndrome (TSS) is a potentially fatal illness caused by infection with the bacterium Staphylococcus aureus. TSS toxin-1 (TSST-1) contains a T-cell epitope with specificity for human V-beta-2. Binding of TSST-1 to the human major histocompatibility complex and T cell receptors activates T cells and triggers the secretion of high amounts of inflammatory cytokines, leading to TSS and potentially death. During this process, CD4 + T cells are inhibited by TSST-1, while regulatory T cells are increased. This suggests a protective immune response by the body in TSS. Thus, TSST-1 can trigger both, an inflammatory response that attacks the body and a protective response. In this review, we discuss the interaction between TSST-1 and T lymphocytes in TSS.
INTRODUCTION
Toxic shock syndrome (TSS), a potentially fatal illness caused by infection with the bacteria, including Staphylococcus aureus (1) , was first reported in 1978 by James K Todd, who described the staphylococcal illness in three boys and four girls aged 8-17 years (2) . Patients with TSS can recover in 2-3 weeks under proper treatment, but can also die within hours. In TSS, Staphylococcus aureus produces a superantigenic toxin, toxic shock syndrome toxin-1 (TSST-1), which is responsible for 50% of nonmenstrual and 100% of all menstrual TSS cases and also plays a role in immune evasion, allowing further invasion of Staphylococcus aureus (3, 4) . Moreover, TSST-1 allows the nonspecific binding of class II major histocompatibility complex (MHC II) to T cell receptors (TCRs), resulting in the activation of polyclonal T lymphocytes, especially human T cells that express V-beta-2, which may represent 5-30% of all host T cells (5) . During the development of TSS, the cross-linking of V-beta-specific regions of the alpha-beta TCR to MHC II molecules on antigen presenting cells (APC) is required to stimulate T cells (5) . TSST-1 therefore plays a key role in TSS through its effect on T cells. In addition to its role in TSS, TSST-1 is associated with an increased number of T cells in nasal polyps (6) . In a recent study, T cells activated by TSST-1 were shown to destroy colorectal tumor cells, particularly under hypoxic conditions (7) . This finding suggests that T cells may adopt certain characteristics during their interaction with TSST-1, which may be promising in immunotherapy not only in TSS but also in tumors. In the present review, we focus on the interaction between TSST-1 and T cells in TSS, and we provide novel insights into the immunotherapy of TSS.
TOXIC SHOCK SYNDROME TOXIN-1 IN THE T CELL-RELATED IMMUNE RESPONSE OF TSS
Although the key role of T cells in TSST-1-induced TSS is well accepted, the involvement of the superantigen TSST-1 in the T cell-related immune response of TSS is poorly understood. TSST-1 is a 22-kDa singlechain polypeptide of 194 amino acid residues that belongs to the family of staphylococcal enterotoxin superantigens (8) . TSST-1 residues essential for its mitogenic activity, such as Tyr 115, Glu 132, His 135, Gln 136, Ile 140, His 141 and Tyr 144, were identified by site-directed mutagenesis (9-16). As superantigen-MHC II binding is a prerequisite for subsequent mitogenic activity, MHCbinding sites on TSST-1 have been identified that are located within residues 39-78 and 155-194 (17) . Thus, residues 115-144 of TSST-1 may be related to T-cell epitopes on TSST-1, which was supported by the threedimensional structure of TSST-1, resolved by X-ray crystallographic analysis (18). Ramesh et al. (19) reported that the synthetic peptides derived from superantigens can serve as classical antigens to activate T cells. Bonventre et al. (20) found a mutation at histidine residue 135 of TSST-1 that yields an immunogenic protein with minimal toxicity. Furthermore, Hu et al. (21) localized the T-cell epitope of TSST-1 to a region between residues 125 and 158. These authors also examined the V-beta specificity of T cells activated by T34 and T58 and found that T34 and T58 possessed two of four TSST-1-targeted V-beta specificities in humans and mice, human V-beta-2 and murine V-beta-15 (21). These findings confirmed that TSST-1 contains a T-cell epitope with specificity for human V-beta-2, and suggest that TSST-1 can specifically activate T cells in TSS. However, because of the lack of an effective approach, the analysis of T cell epitopes is still limited.
High mobility group box-1 (HMGB-1) is an important chromatin protein secreted by activated monocytes that interacts with nucleosomes, transcription factors and histones and has been identified as a key late mediator of endotoxic shock (22). Although the translocation and secretion of HMGB-1 mediated by TSST-1 is dependent on the presence of both activated T cells and monocytes, nuclear HMGB-1 is released from TSST-1-induced T cells (23). This finding provided insight into the interaction between TSST-1 and T cells and the basis for investigating the potential of targeting HMGB-1 for TSST-1-induced TSS therapy.
T-cells activated by TSST-1 secrete IFN-gamma, which mediates the TSST-1-induced hypersensitivity to LPS, resulting in inflammation in TSS (24). During the acute phase of menstrual TSS, T cells are persistently reactive to TSST-1 (25). This may partly explain the association of TSST-1 production with expansion of TSST-1-reactive T cells and a rapid worsening of symptoms in TSS. In addition to IFN-gamma, staphylococcal enterotoxin A, which is produced simultaneously with TSST-1 by Staphylococcus aureus, has a collaborative effect with TSST-1 in T cell activation and TNF secretion (26).
TSST-1 BINDING SITE IN T CELL RECEPTORS
TSST-1 was shown to induce T cell activation in both animal models and patients with TSS (27-29). In this process, T cell activation by staphylococcal TSST-1 is dependent on TCR recognition of the intact toxin molecule bound to a nonpolymorphic region of the Ia molecule (30). Furthermore, Dennig and colleagues (31) demonstrated that although costimulation for TSST-1-induced T cell proliferation is provided by human leukocyte antigen (HLA) class II negative accessory B cells, TSST-1 directly binds TCR, and TSST-1-induced T cell proliferation is involved in the BB1/CD28 pathway (31). This differs from typical T cell recognition, in which an antigen is taken up by an APC, processed, expressed on the cell surface in complex with MHC II in a groove formed by the alpha and beta chains of class MHC II, and recognized by an antigenspecific T cell receptor.
A study investigating the binding sites of MHC II and TCR showed that the MHC II binding site is located in the hydrophobic region of the NH 2 -terminal domain, and the TCR binding site is primarily in the major central groove of the COOH-terminal domain (32). This study characterized TSST-1 binding to TCR and MHC molecules at the molecular level and showed that MHC class IIassociated peptides that do not promote TSST-1 presentation can be converted into "promoting" peptides by the progressive truncation of C-terminal residues. Furthermore, A different study confirmed that the length of the MHC II-bound peptide is crucial in the presentation of TSST-1 by splenic APC and that different subpopulations of APCs are equally peptide dependent in TSST-1 presentation (33). This finding suggested that the MHC II binding site affects the binding of T cells.
In addition to the MHC II receptor, TCR is critical for T cell activation induced by TSST-1. Cullen et al. (34) showed that a functional site defined by a TSST-1 mutation at histidine 135 affects toxin interactions with TCR instead of MHC II, suggesting a key role for TCR in the interaction between TSST-1 and T cells in TSS. A recombinant human TCR V-beta-2 fusion protein (V-beta-2 sol) produced in Escherichia coli was shown to have specificity in binding to TSST-1 in vivo (35) . An in vitro study demonstrated that in response to TSST-1 stimulation, TCR V-gamma-2 is expressed in purified bovine WC1+ gamma delta T cells, as well as TCR V-gamma-1, and these WC1+ gamma delta T cells can be driven to proliferate by TSST-1 (36). In human peripheral blood mononuclear cells subjected to TSST-1 stimulation, early V-beta-2 specific TCR activation is accompanied by CD80/CD86 and CD154 costimulation, which may determine TSST-1-induced proinflammatory cytokine responses including IL-2, IFNgamma and TNF-alpha (37). In summary, TSST-1 stimulates T cell activation via V-beta-2 specific TCR activation along with CD80/CD86 and CD154 costimulation in TSS, which promotes inflammation by controlling the secretion of TSST-1-induced cytokines ( Figure 1 ). During this process, in which the T cell immune response is stimulated and activated following local or even systemic inflammation, inflammatory cytokines circulate in the body with blood, and TCR V-gamma-2 plays a key role. In a follow-up study, a panel of high affinity TCRs for TSST-1 was generated to investigate the molecular details of the interaction between TSST-1 and human V-beta-2.1 TCR, and the findings showed that the energetic importance of a single human V-beta-2.1 wild-type residue may determine the restriction of TSST-1 specificity to only this human V-beta region (38).
Since V-beta-2 TCR activation is specific in early TSS, an anti-human V-beta-2 monoclonal antibody can be used to detect human T-cells that react with TSST-1 (39). Considering the importance of the V-beta-2 TCR in TSST-1-induced TSS, T cells marked with V-beta-2 specific TCR were used to achieve an early and definitive diagnosis of TSS in two cases, which showed that the use of these T cells is a promising approach for the rapid and definitive diagnosis of TSS (40). Later, Wenisch et al. (41) confirmed the diagnostic value of V-beta-2-positive T-cells in a case report that included three patients. These authors also reported that the diagnosis of TSS based on the detection of V-beta-2 positive T-cells was significantly faster than the traditional standard of the Centers for Disease Control and Prevention (CDC), which could be attributed to a complicated clinical picture or the delay caused by waiting for the results of microbiologic investigations (41).
In addition to TCR mutations, antigen receptor mutations can also affect TSST-1-induced T cell activation. Although TSST-1 does not activate V-beta-8.2 T cells, a fas antigen receptor mutation was found to be associated with TSST-1-induced lethal shock in V-beta-8.2 TCR transgenic mice (42). Thus, the role of antigens should be considered in the T cell response in TSS. In addition, factors other than neutralizing antibodies and the frequency of V-beta-2 T lymphocytes can also determine immunological responsiveness to TSST-1. The differential responsiveness of lymphocytes to TSST-1 may form the basis of interindividual variations in susceptibility to menstrual TSS (43). In summary, TCRs are crucial in the TSST-1-induced T cell response in TSS, and MHC II may play a role in the TCR effect. Antigen and interindividual variations are involved in this complex process.
T CELL SUBSET IN TSST-1-INDUCED TSS
In TSS, TSST-1 binds to human MHC and TCR molecules, promoting T cell activation and the production of high amounts of inflammatory cytokines, finally leading to TSS and potentially death. Therefore, TSST-1 stimulates T cell proliferation in TSS. Even in neonatal TSS, the adult-type T cell responds to TSST-1 (44) . Lymphopenia and impaired cellular immunity were found in TSS patients, although at a lower incidence than in patients with septic shock (45) , suggesting the involvement of T cell immune responses in TSST-1 induced TSS. Recent studies have provided information on the specific T cell subset associated with the development of TSS. CD4+ T cells, which can orchestrate immune responses against a wide variety of pathogenic microorganisms and regulate/suppress immune responses both to control autoimmunity and to adjust the magnitude and persistence of responses (46) , may be inhibited by TSST-1 (47). CD4+ T cells are important mediators of immunologic memory, and when their numbers are diminished or their functions are lost, the individual becomes susceptible to a wide range of infectious disorders. Inhibition of CD4+ T cells by TSST-1 results in immunological dysfunction in TSS patients.
During and after the acute phase of TSS, there is no reduction in peripheral T cells. By contrast, upregulation of the T cell activity marker HLA-DR was reported in a TSS patient during the acute phase and its levels declined significantly after the acute phase (27). The TSST-1 peptide binds to the HLA-DR, a MHC class II cell surface receptor, and the complex is presented to many TCRs on Thelper cells. These findings indicate the activation and proliferation of T cells in TSS. However, another T cell activity marker, CD25, is not altered in TSS (27). This is different from streptococcal TSS, in which the CD25 T cell subset and HLA-DR are increased, as well as the gamma delta T cell subset (48) . An important difference in T cells between staphylococcal TSS and streptococcal TSS is the expression of CD25. Although CD25 is an activation marker for T cells, the different T cell subtypes have different effects on the expression level of CD25. Dauwalder et al. (49) showed that TSS patients had increased amounts of circulating regulatory T cells (Tregs), which are CD25+ T cells. Since Tregs are vital for preventing autoimmunity and immune-mediated inflammation, an increase in circulating Tregs may be reflective of a protective immune response to TSST-1. Furthermore, these authors did not observe decreased lymphopenia or HLA-DR expression, which is consistent with Arvand's findings (27). Therefore, Tregs were identified as effectors in TSST-1 associated TSS, suggesting a key role of Tregs in TSS pathogenesis and immunotherapy.
Tregs are poised to sense IL-10, and the IL-10 receptor IL-10R on Treg cells plays a pivotal role in their function (50) . IL-10, a cytokine with pleiotropic effects in immunoregulation and inflammation, was able to inhibit the production of inflammatory cytokines induced by TSST-1 in TSS, such as TNF-alpha, interleukin (IL)-1, IL-6 and interferon (IFN)-gamma (51) . Although the inhibitory effect of IL-10 on T cell proliferation was not as strong as its effect on inflammatory cytokines, it could inhibit TSST-1 induced T cell proliferation by more than 10% (51). Kalyan et al. (52) reported a decreased level of IL-10 and increased levels of IFN-gamma, TNF-alpha and IL-2 induced by TSST-1. They further demonstrated that depletion of gamma delta T cells completely abrogated this effect. This finding suggests that peripheral gamma delta T cells can markedly modulate IL-10 dependent antiinflammatory responses and TSST-1 associated proinflammatory responses (Figure 2 ). These findings indicate that IL-10 may be involved in the immune response of Tregs and gamma delta T cells, and suggest the possible importance of IL-10 for immunotherapy against TSST-1-induced TSS.
CONCLUSIONS
In this review, we summarized the current knowledge on the interaction between TSST-1 and T lymphocytes in TSS. TSST-1 contains a T-cell epitope with specificity for human V-beta-2. Binding of TSST-1 to human MHC and TCR molecules results in the activation of T cells and the secretion of high amounts of inflammatory cytokines, finally leads to TSS and death. During this process, CD4 + T cells are inhibited by TSST-1, while Tregs are upregulated. This suggests a protective immune response by the body in TSS. Thus, TSST-1 can lead to both an inflammatory response that results in destruction and a protective response. Therefore, the underlying mechanism of TSST-1 induced TSS may involve an imbalance between the destructive and protective responses of the body. Immunotherapy against TSST-1-induced TSS may be a promising approach in the future, especially considering the rise in antibiotic resistance and the fact that Staphylococcus aureus is becoming one of the major resistant pathogens. 
